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Abstract: Rheumatoid arthritis is a chronic, progressive autoimmune disease associated with
inflammation and destruction of joints and systemic effects, which result in significant impact
on patient’s quality of life and function. Tofacitinib was approved for the treatment of rheumatoid arthritis in the USA in 2012 and subsequently in other countries, but not by the European
Medicines Agency. The goal of this review was to evaluate the impact of tofacitinib on patientreported and patient-specific outcomes from prior clinical studies, focusing on quality of life,
functionality, pain, global disease assessment, major adverse consequences, and withdrawals.
A total of 13 reports representing 11 clinical studies on tofacitinib in rheumatoid arthritis
were identified through PubMed and reference lists in meta-analyses and other reviews. Data
on improvements in patient-driven composite tools to measure disease activity in rheumatoid
arthritis, such as the Health Assessment Questionnaire, served as a major outcome evaluated in
this review and were extracted from each study. Additional data extracted from those clinical
studies included patient assessment of pain (using a 0–100 mm visual analog scale), patient
global assessment of disease (using a 0–100 mm visual analog scale), patient withdrawals,
withdrawals due to adverse effects or lack of effect, and risk of serious adverse effects, serious
infections, and deaths. Tofacitinib 5 mg bid appears to have a favorable impact on patient outcomes related to efficacy and safety when compared with baseline values and with comparator
disease-modifying antirheumatic drugs and placebo. Improvements were seen in the composite
and individual measures of disease activity. Serious adverse effects, other adverse consequences,
overall withdrawals, and withdrawals due to adverse effects and lack of efficacy are similar or
more favorable for tofacitinib versus comparator disease-modifying antirheumatic drugs and
placebo. At this point, tofacitinib appears to have an important role in the treatment of rheumatoid arthritis through improvement in these patient outcomes. However, it may require years of
additional clinical studies and postmarketing surveillance to fully characterize the benefit-to-risk
ratio of tofacitinib in a larger and diverse patient population.
Keywords: tofacitinib, rheumatoid arthritis, patient-reported outcomes, quality of life
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Rheumatoid arthritis is a chronic, progressive autoimmune disease of joints associated
with inflammation and destruction of joints and systemic effects.1,2 The most recent
rheumatoid arthritis treatment guidelines were developed by the American College of
Rheumatology (ACR) in 2012, the European Union League Against Rheumatism in 2013,
and Canada in 2012.3–5 Tofacitinib was approved as a second-line treatment for moderateto-severe rheumatoid arthritis in patients who have inadequate response or intolerance
to methotrexate in the USA in 2012 at 5 mg bid. It was subsequently approved in Japan,
Kuwait, United Arab Emirates, Argentina, and Canada at 5 mg bid and in Russia and
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Switzerland at both 5 and 10 mg bid.6 However, in 2013, the
European Medicines Agency (EMA) did not approve tofacitinib after two reviews due to concerns related to the risks of
serious infections and other severe adverse effects.7 Tofacitinib is now approved in 40 countries and Pfizer Laboratories
(New York, USA) plans to resubmit to the EMA for approval
later in 2015.8 The US Food and Drug Administration (FDA)
approved tofacitinib with labeling that includes warnings on
serious infections and malignancies.9 The warnings are similar
to those seen in the labeling for biologic disease-modifying
antirheumatic drugs (DMARDs) used in the treatment of
rheumatoid arthritis. Tofacitinib does not appear in the ACR
or Canadian guidelines but is mentioned in the European
Union League Against Rheumatism guidelines. The clinical
use and sale of tofacitinib continues to expand, particularly
in the USA.10,11 The impact of tofacitinib on the clinical and
laboratory measures of rheumatoid arthritis (ACR20, ACR50,
ACR70, DAS28, etc) is well documented in reviews and metaanalyses,12–20 but these do not focus on the impact on outcomes
from the patient’s perspective and do not include the latest
studies. Patient-reported outcomes data are provided in almost
all published studies and may also be provided as additional
details in subanalyses of original studies or supplementary
data. Pharmacoeconomic analyses were not included in this
review in order to focus specifically on patient-reported and
patient-related outcomes documented in clinical studies. The
objectives of this review are to collect and evaluate data related
to the impact of tofacitinib on patient-reported outcomes (quality of life, functionality, pain, and global disease assessment),
major adverse consequences, and withdrawals.

Methods
Clinical studies on tofacitinib in rheumatoid arthritis served
as the primary source for the data collected in this review.
The selection criteria also included studies or reports written in English, blinded and open-label studies, prospective
and retrospective, containing the original publication of the
data, and data provided on at least one of the patient-specific
outcome measures noted as follows. The studies were identified through a number of methods, initially through PubMed
searches using the following search terms: tofacitinib,
CP-690550, and rheumatoid arthritis and limiting the search
to clinical studies. The same terms were used in searching
for articles in the following databases: Cochrane Library,
EBSCO Medline Complete, International Pharmaceutical
Abstracts, ScienceDirect, and Scopus. The reference lists in
meta-analyses and review articles on tofacitinib were also
searched for clinical studies.
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Selection criteria for the studies included any studies that
were prospective Phase II, Phase III, or other original studies
evaluating efficacy and/or safety of tofacitinib in rheumatoid arthritis. The authors extracted specific data from each
study and any supplementary documents provided and then
tabulated data on one or more specific outcomes. Data were
verified through review by at least one other author.
Each of the studies selected was searched for data within
each of the following general categories measures: patientreported composite measures and specific measures of disease outcomes, withdrawals, and serious adverse effects or
consequences. The patient-reported composite measures of
disease outcomes evaluated in each study, based on recommendations from the ACR and other rheumatology societies
and experts, included: Health Assessment Questionnaire
(HAQ, HAQ-II, and HAQ-Disability Index [HAQ-DI]),
Functional Assessment of Chronic Illness Therapy Fatigue
Scale, Short Form 36-Item Health Survey, Short Form 36-Item
Arthritis Specific Health Index, Patient Activity Scale, Patient
Activity Scale II, Routine Assessment of Patient Index Data
with 3 measures, Arthritis Impact Measurement Scale (AIMS,
AIMS2), European Quality of Life Measure, Multidimensional Health Assessment Questionnaire, Modified Health
Questionnaire, and Rheumatoid Arthritis Quality of Life.21–24
The patient-reported specific measures of disease activity
included patient assessment of pain (using a 0–100 mm visual
analog scale) and the patient global assessment of disease
(using a 0–100 mm visual analog scale). Withdrawal data
used in this review included total withdrawals, withdrawals
due to lack of efficacy, and withdrawals due to adverse effects.
The data on serious adverse effects or consequences included
serious adverse effects, serious infections, cancers, and deaths
that occurred during the studies.21–24
The data extracted included improvement from baseline
in units measured and percent improvement from baseline
for HAQ-DI, patient assessment of pain, patient global
assessment of disease, and other measures. Therefore, these
numbers are positive in value to demonstrate improvement
rather than the negative values reported in the studies that
reflect improvement in those measures. Frequency counts and
the percent of those counts based on the size of the entering
groups were provided for the other measures. Percentages
and visual analog scale results were rounded off to whole
numbers.
The recommended dose for tofacitinib in the USA is 5 mg
bid,9 but lower and higher dosages have been used in clinical
studies, and approval in Russia and Switzerland includes both
5 and 10 mg bid.6 In order to simplify the data tables, data from
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1 and 3 mg bid dosage groups were combined, data from 10 bid
and 20 mg once-daily dosage groups were combined, and data
from 15 and 30 mg bid dosage groups were combined. Data
from the 5 mg bid groups were listed separately.
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Results
A total of 12 clinical studies reported in 14 articles were
identified, met the selection criteria, and were used in this
review (Table 1).25–44 Two reports, which included subanalyses of data from studies, were also included.25,26,33,37 Recent
reports that did not meet the selection criteria included a
Phase I study, which was short in duration and lacked efficacy measures.39 A report of pooled adverse effect data from
13 studies was not the original study reporting those data,
but select data from that report was used in describing the
risk factors for serious infections.40
Another report of pooled data from studies was used to
provide data on the development of cancers in patients on
tofacitinib.41 A total of eleven studies were double-blind
and randomized and one study was an open-label long-term
extension study.25,27–36,38 All studies were parallel in design
and a few studies also included a sequential design for
patients who started on placebo and were placed on tofacitinib after 3–6 months (Table 1). Tofacitinib was compared
with placebo, methotrexate, and/or adalimumab as monotherapy in five double-blind studies.25,28,30,35,38 Tofacitinib was
combined with methotrexate or other nonbiologic DMARDs
in the other six double-blind studies,27,29,31–34 including one
study that compared tofacitinib, adalimumab, and placebo
in patients also receiving methotrexate.31

Patient-reported composite health
assessment measures
All 12 studies used the HAQ-DI as the primary patientreported composite health assessment measure and 3 studies used additional patient-reported composite measures
(Table 2). A change from baseline of greater than 0.22 is
widely considered to be the minimum clinically important
difference.22,27,30 However, one study used the threshold of
a change of greater than 0.3 in classifying those as being
HAQ-DI responders.26 Across most dosage ranges studied,
tofacitinib showed clinically or statistically significant
changes in baseline HAQ-DI scores when compared with placebo or comparator drug (Table 2). Changes in the HAQ-DI
score were dose dependent in the vast majority of the studies
using multiple dosages showing a greater improvement in
the higher dosages, with one exception.29 Tofacitinib 5 mg
bid, the currently approved and most commonly studied
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dosage, was associated with average changes in HAQ-DI
ranging from 0.4 to 0.9, all above the threshold of 0.22 for a
clinical important improvement. Of the 12 studies reporting
HAQ-DI findings, 9 showed a statistically significant change
in HAQ-DI for tofacitinib 5 mg bid compared with placebo
or comparator drug.
Additional patient-reported composite health assessment
measurement tools were used in four reports. The Functional
Assessment of Chronic Illness Therapy-fatigue instrument
demonstrated that tofacitinib 5 and 10 mg bid were statistically superior to placebo.30,34 The Short Form 36-item survey
instrument demonstrated statistically significant improvement
in the physical component scale in all studies reporting this
outcome, but only in two studies for the mental component
scale when comparing tofacitinib 5 mg bid monotherapy and
combination therapy with placebo (Table 2).26,27,37,38 Some
improvement was seen in the Medical Outcomes Study Sleep
Scale, but it was not statistically significant.37
Measures of health status improved either clinically,
statistically, or both, in all studies investigating tofacitinib
5 mg bid against baseline, placebo, or comparator drug
when studied as monotherapy or in combination with other
agents. Studies, which ranged in length from 6 weeks to
60 months, showed benefits in health status early in treatment and continued through longer periods of time. Given
the studies that have been conducted so far, tofacitinib
shows definite improvement in patient’s quality of life and
functional domains.

Patient’s assessment of pain and patient’s
global assessment of disease
Data on patient’s assessment of pain and/or patient’s global
assessment of disease were available in seven clinical
studies (Table 3). Improvements in pain and global assessments were similar within each group when comparing
monotherapy with combination therapy studies, except for
the tofacitinib low-dose groups (1–3 mg bid). Tofacitinib
5 mg bid was associated with a 45%–54% improvement in
patient’s assessment of pain and a 44%–60% improvement
in patient’s global assessment of disease. The tofacitinib
1–3 mg bid dosage groups were associated with less to similar improvement (23%–56%) and the tofacitinib 10–30 mg
bid dosage groups were associated with similar to slightly
higher improvements (39%–62%) in pain and global assessment of disease. However, placebo was associated with less
improvement, ranging from 15% to 29% improvement in
patient’s assessment of pain ratings and 23%–39% improvement in patient’s global assessment of disease ratings.
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Table 1 Studies included in this review of patient outcomes associated with the use of tofacitinib in rheumatoid arthritis
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Design

Tofacitinib dose
(no of patients)

Tofacitinib DMARD monotherapy studies
Phase II, double-blind
5 mg bid (61)
15 mg bid (69)
30 mg bid (69)
Phase II, double-blind
1 mg bid (54)
3 mg bid (51)
5 mg bid (49)
10 mg bid (61)
15 mg bid (57)
Phase III, double-blind
5 mg bid (243)
10 mg bid (245)
Placebo then 5 or 10 mg bid (120)a
Phase III, double-blind
5 mg bid (373)
10 mg bid (397)
Phase II, double-blind
1 mg bid (53)
3 mg bid (53)
5 mg bid (52)
10 mg bid (53)
15 mg bid (54)
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
Phase II, double-blind
Methotrexate plus:
1 mg bid (28)
3 mg bid (28)
5 mg bid (28)
10 mg bid (28)
Phase II, double-blind
Methotrexate plus:
1 mg bid (71)
3 mg bid (68)
5 mg bid (71)
10 mg bid (75)
15 mg bid (75)
20 mg od (80)
Phase III, double-blind
Methotrexate plus:
5 mg bid (204)
10 mg bid (201)
Placebo then 5 mg bid (56)a
Placebo then 10 mg bid (52)a
Phase III, double-blind
Methotrexate plus:
5 mg bid (321)
10 mg bid (316)
Placebo then 5 mg bid (81)a
Placebo then 10 mg bid (79)a
Double-blind
Nonbiologic DMARD plus:
5 mg bid (318)
10 mg bid (318)
Placebo then 5 mg bid (79)a
Placebo then 10 mg bid (80)a
Phase III, double-blind
Methotrexate plus:
5 mg bid (133)
10 mg bid (134)
Placebo then 5 mg bid (66)a
Placebo then 10 mg bid (66)a
Tofacitinib monotherapy and combination DMARD study
Open-label, long-term extension
With/without nonbiologic DMARDs:
5–10 mg bid (4,102)

Comparator(s)
(no of patients)

Duration and
reference

Placebo (65)

6 weeks25,26

Placebo (59)
Adalimumab (53)

24 weeks26

6 months30

Methotrexate (186)

24 months35

Placebo (52)

12 weeks38

Methotrexate plus:
Placebo (28)

12 weeks27

Methotrexate plus:
Placebo (69)

24 weeks29

Methotrexate plus:
Placebo (69)
Adalimumab (204)

12 months31

12 months32

1 year34

6 months33,37

48 months36

Note: aOn placebo for 3–6 months, then randomly assigned to tofacitinib at the dose indicated.
Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug; QD, daily or once daily.
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Table 2 HAQ-DI and other composite measures
Outcome

Improvement from baseline in units (%)
Tofacitinib
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1–3 mg bid

Placebo
5 mg bid

10 mg bid
or 20 mg od

15–30 mg
bid
0.7 (44%)
0.74* (30 mg bid)
0.82 (51%)

Tofacitinib DMARD monotherapy studies
HAQ-DI
HAQ-DI
HAQ-DI
0.25–0.44 (16%–29%)

0.6 (35%)
0.6*
0.51 (36%)

0.66 (44%)

HAQ-DI
HAQ-DI

0.50*
0.9 (60%)*

0.57*
1.0 (67%)*

0.3 (18%)
0.2
0.25 (16%)

Comparator
DMARD

Adalimumab
0.35 (24%)

0.19
Methotrexate
0.7 (47%)

HAQ-DI responders#
(57%)*
HAQ-DI responders#
(53%)*
(56%)
HAQ-DI responders#
(55%)*
(74%)*
(82%)*
FACIT-Fatigue
6.7*
8.0*
FACIT-Fatigue
2.5–5.4*
7.5*
8.5*
SF-36 PCS
8.3*
SF-36 MCS
5.3
SF-36 PCS responders$ (62%)*
(82%)*
(86%)*
SF-36 MCS responders$ (45%)
(74%)*
(66%)
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
HAQ-DI
0.38–0.41 (32%–35%)¶ 0.49 (41%)* 0.57 (48%)*
HAQ-DI
0.34–0.48 (22%–35%)* 0.49 (34%)* 0.39–0.53
(29%–36%)*
HAQ-DI
0.55 (37%)* 0.61 (44%)*
HAQ-DI
0.40 (28%)
0.54 (39%)*
HAQ-DI
0.44 (31%)* 0.53 (37%)*
HAQ-DI
0.43 (27%)* 0.46 (31%)*
HAQ-DI responders#
(54%–63%)*
(79%)*
(81%)*
FACIT-Fatigue
5.8^,*
6.8^,*
FACIT-Fatigue
6.3*
4.6^,*
SF-36 PCS
5.7 (18%)*
6.6 (20%)*
SF-36 PCS responders$ (75%)¶
(79%)*
(76%)*
SF-36 PCS responders$
(68%)*
(66%)*
SF-36 MCS
3.5 (8%)*
4.0 (9%)*
SF-36 MCS responders$ (58%)¶
NR
NR
SF-36 MCS responders$
(54%)*
(50%)*
MOS-SS
6.8 (16%)
5.8 (14%)
Tofacitinib monotherapy and combination DMARD study
HAQ-DI
0.8 (57%)

(76%)*

Duration and
reference

6 weeks25
6 weeks26
24 weeks28
6 months30
24 months35

8.0*
9.9*
9.81*
(83%)*
(56%)

(36%)
(32%)
(21%)
2.8
–1.4
2.7
2.64
(25%)
(27%)

6 weeks26
6 months30
12 weeks38
6 months30
12 weeks38
6 weeks26
6 weeks26
12 weeks38
12 weeks38

0.43 (30%)*

0.05 (4%)
0.16 (13%)

12 weeks27
24 weeks29

(73%)*

0.24 (16%)
0.15 (11%)
0.16 (12%)
0.18 (11%)
(33%)
2.0^
1.1
2.0 (7%)
(25%)
(49%)
0.4 (1%)
(29%)
(37%)
3.8 (8%)

Adalimumab
0.49 (33%)

12 months31
12 months32
1 year34
6 months33
12 weeks27
1 year34
6 months37
6 months37
12 weeks27
6 months37
6 months37
12 weeks27
6 months37
6 months37
60 months36

Notes: *P,0.05 for tofacitinib at this dose versus placebo or comparator; P,0.05 for tofacitinib at this dose versus placebo or comparator for only one of the two groups;
#
HAQ-DI responders = improvement of $0.22 or $0.30 units on HAQ-DI; $SF-36 MCS or PCS responders = improvement of $2.5 units from baseline on SF-36 MCS or
PCS; ^estimated from a graph presented in the published study.
Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-fatigue instrument;
HAQ-DI, Health Assessment Questionnaire-Disability Index; MOS-SS, Medical Outcomes Study Sleep Scale; SF-36, Short Form 36-item survey instrument; SF-36 MCS, SF-36
Mental Component Scale; SF-36 PCS, SF-36 Physical Component Scale.
¶

In monotherapy studies, methotrexate was associated with
47% improvements in patient’s assessment of pain and global
assessment of disease, which was comparable to tofacitinib
5 mg bid.35 Adalimumab was associated with 30%–32%
improvements in patient’s assessment of pain and global
assessment of disease, which are lower than those seen with
tofacitinib 5 mg bid.28 In summary, tofacitinib is associated
with improvements in patient-reported assessment of pain
and global assessment of disease.
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Total withdrawals and withdrawals
due to lack of efficacy
Total withdrawals and withdrawals due to lack of efficacy
for tofacitinib, comparators, and placebo demonstrate possible trends across type of study (monotherapy vs combination
therapy), tofacitinib dose, and duration of study (Table 4).
Tofacitinib as monotherapy is associated with fewer total
withdrawals (range 5%–21%) compared with tofacitinib as
combination therapy with other DMARDs (range 14%–25%)
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Table 3 Patient-reported assessment of pain and global assessment of disease in tofacitinib studies
Outcome

Improvement from baseline in units (%)
Tofacitinib

Placebo
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1–3 mg bid

5 mg bid

10 mg bid
or 20 mg od

Tofacitinib DMARD monotherapy studies
Paina
34 (50%)
Paina
14–18 (23%–29%)
31 (48%)

34 (54%)

Paina

32 (54%)

35 (58%)

Patient globala
Patient globala

35 (50%)
31 (46%)

33 (53%)

32 (53%)

35 (58%)

16–19 (26%–32%)

Patient globala

15–30 mg bid

40–44 (59%–66%)
36 (56%)

39–40 (61%–62%)
36 (57%)

Tofacitinib plus methotrexate or other nonbiologic DMARD studies
Paina
23–33
31
38
Paina
22–24 (37%–44%)*
27 (50%)*
22–26 (39%–43%)*
24 (43%)*
Paina
27*
25*
Paina
26 (45%)*
30 (52%)*
Patient globala
27–38
38
38
Patient globala
28–32 (44%–56%)*
34 (60%)*
30–34 (51%–56%)*
37 (61%)*
Patient globala
26 (44%)*
29 (51%)*

10 (15%)
17 (27%)

15 (23%)
16 (27%)

Comparator
DMARD

Adalimumab
21 (32%)
Methotrexate
28 (47%)
Adalimumab
19 (30%)
Methotrexate
27 (47%)

6
13 (25%)
8
16 (29%)
7
23 (39%)
14 (25%)

Duration and
reference

6 weeks25
24 weeks28
24 months35
6 weeks25
24 weeks28
24 months35

12 weeks27
24 weeks29
6 months33
12 months32
12 weeks27
24 weeks29
12 months32

Notes: *P,0.05 versus placebo or comparator; apatient assessment of pain and global assessment of disease on a 0–100 mm visual analog scale.
Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug.

Table 4 Withdrawals in general and withdrawals due to lack of efficacy in tofacitinib studies
Event

Number of events (% of group)
Tofacitinib
1–3 mg bid

Placebo
5 mg bid

Tofacitinib DMARD monotherapy studies
Wd all
3 (5%)
Wd all
22 (21%)
6 (12%)
Wd all
Wd inefficacy
Wd inefficacy

6 (6%)

Wd inefficacy

10 mg bid
or 20 mg od

6 (10%)

15–30 mg bid

Comparator
DMARD

Duration and
reference

26 (19%)
5 (9%)

17 (26%)
16 (27%)
4 (8%)
8 (12%)
4 (7%)
2 (4%)

12 weeks38

5 (18%)
15 (22%)
6 (5%)

12 weeks27
24 weeks29
6 months33
12 months32
1 year34
12 weeks27
24 weeks29
6 months33
12 months32
1 year34

4 (8%)

6 (6%)

2 (4%)
1 (2%)
1 (2%)

1 (2%)

2 (4%)
2 (1%)
0

2 (2%)

0

0

0

Tofacitinib plus methotrexate or other nonbiologic DMARD studies
Wd all
7 (13%)
5 (18%)
7 (25%)
Wd all
20 (14%)
15 (21%)
22 (14%)
15 (20%)
Wd all
38 (19%)
44 (23%)
Wd all
71 (22%)
51 (16%)
Wd all
53 (17%)
64 (20%)
Wd inefficacy
1 (2%)
0
0
Wd inefficacy
2 (1%)
1 (1%)
1 (1%)
0
Wd inefficacy
5 (3%)
11 (6%)
Wd inefficacy
7 (2%)
3 (1%)
Wd inefficacy
16 (4%)
12 (4%)
Tofacitinib monotherapy and combination DMARD study
Wd all
852 (21%)

13 (8%)
1 (4%)
5 (7%)
2 (2%)

Adalimumab
16 (30%)

Adalimumab
5 (9%)

6 weeks25
24 weeks28
12 weeks38
6 weeks25
24 weeks28

60 months36

Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug; Wd, withdrawal.
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and adalimumab monotherapy (30%) or placebo monotherapy (26%–27%). However, there is no apparent consistent
pattern of differences in total withdrawal rates in combination therapy studies comparing tofacitinib with placebo or
among the different doses of tofacitinib in monotherapy and
combination therapy studies (Table 4).
The withdrawal rates due to lack of efficacy are lower for
tofacitinib monotherapy groups (range 0%–6%) compared with
adalimumab and placebo monotherapy groups (range 7%–12%).
However, the withdrawal rates due to lack of efficacy were
similar for tofacitinib monotherapy groups (range 0%–6%),
tofacitinib–DMARD combination groups (range 0%–6%), and
placebo–DMARD combination groups (2%–7%). Withdrawal
due to lack of efficacy may be higher for tofacitinib 1–3 mg
bid monotherapy groups (6%) compared with tofacitinib at
higher doses (0%–2%) in one study,28 but not in the combination therapy studies.
In long-term extension studies, the rate of withdrawal
secondary to all causes was reported to be 21% for tofacitinib
5 mg bid or tofacitinib 10 mg bid, with or without background
DMARD therapy.36 Although those receiving efficacy is
achieved and sustained over 48 months, the efficacy over
time was likely influenced by the decreased persistence on
tofacitinib therapy over time.
In summary, total withdrawals and withdrawals due to
lack of efficacy for tofacitinib appear to be similar or fewer
than withdrawals from placebo or other comparators.

Withdrawal for adverse drug reactions
During tofacitinib DMARD monotherapy studies, the percentage of withdrawals from tofacitinib secondary to adverse
drug reactions ranged from 1% to 7% in studies lasting
6 weeks to 6 months and increased to a range of 10%–13% in
a 24-month study (Table 5).35 Additionally, these percentages
remained comparable between the 5 and the 10 mg bid or
20 mg od dose arms across the monotherapy studies. Studies
of tofacitinib–DMARD combination from 12 weeks to 1 year
demonstrated similar percent of withdrawal rates secondary
to adverse events in the 5 and the 10 mg bid or 20 mg od
dose arms, ranging from 1% to 14% (Table 5). There were
no apparent consistent trends for withdrawal due to adverse
effects when comparing tofacitinib with comparators or
placebo (Table 5). Furthermore, discontinuations secondary
to adverse effects in long-term extension studies occurred in
11% of patients and had an incidence rate of 7.3 events per
100 patient-years, with the most frequent types of adverse
effects resulting in withdrawal due to laboratory study

Patient Related Outcome Measures 2016:7

Tofacitinib and patient outcomes in rheumatoid arthritis

abnormalities, infestations and infections, and neoplasias.36
Additional reported adverse drug reactions leading to trial
withdrawal consisted of neutropenia, leukopenia, myocardial ischemia, moderate bronchitis, lymphadenopathy, and
pyelonephritis among others.25 In summary, withdrawals due
to adverse effects increase with increased duration but are
generally comparable across the different doses of tofacitinib
and with placebo and other comparator DMARDs.

Serious adverse drug reactions
The percent of serious adverse events during tofacitinib
DMARD monotherapy studies in the 5 and 10 mg bid arms
appeared to increase with study duration from 0% to 7% in
6-week to 6-month studies compared with 11% in a 24-month
study (Table 5). Tofacitinib DMARD monotherapy studies
with durations of 6 and 24 weeks reported no cases of serious
adverse drug reactions in the 5 mg bid group, 2% occurrence
in a 6-month study, and 11% occurrence in 24-month study.
There was no apparent consistent pattern of increases in serious adverse drug reactions seen with higher doses compared
with lower doses. In combination DMARD studies, tofacitinib
was associated with similar occurrence of serious adverse drug
events across all dosages of tofacitinib. In addition, long-term
extension studies reported an incidence rate of 11.1 serious
adverse events per 100 patient-years with 15% of patients
experiencing serious adverse events.36 Similar to withdrawals due to adverse effects, the rates of serious adverse effects
increased as study duration increased, but were generally
comparable across the different doses of tofacitinib and with
placebo and other comparator DMARDs.

Serious infections
The occurrence of serious infections in various studies ranged
from 1% to 3% and was similar with respect to duration of
therapy or intervention in both monotherapy and combination
studies (Table 5). Incidence rates of 4.17 serious infections
per 100 patient-years with tofacitinib 5 mg bid, 2.32 per
100 patient-years with tofacitinib 10 mg bid, and 3.68 per 100
patient-years with placebo were reported in a 1-year study.34
Comparatively, serious infections occurred in 184 patients
(4%) with an incidence rate of 3.1 events per 100 patientyears during long-term extension studies.36
An analysis of infections in all prior Phase II, Phase III,
and long-term extension studies was not used in the
initial data, but provides data on predictors of serious
infections.40 The independent predictors associated with
elevated risk for serious infections included: age $65 years
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Table 5 Major safety events: serious adverse drug reactions, serious infections, cancers, deaths, and withdrawal due to lack of efficacy
in tofacitinib studies
Event

Number of events (% of group)
Tofacitinib
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1–3 mg bid

Placebo
5 mg bid

10 mg bid
or 20 mg od

15–30 mg bid

Tofacitinib DMARD monotherapy studies
Wd ADR
1 (2%)
Wd ADR
2 (2%)
1 (2%)

1 (2%)

Wd ADRs
Wd ADRs

3 (1%)
40 (11%)

11 (4%)
41 (10%)

2 (4%)
0
0

3 (6%)

6 (2%)
40 (11%)

11 (4%)
43 (11%)

1 (2%)
1 (,1%)
11 (3%)

1 (2%)
4 (1%)
8 (2%)

1 (2%)

0
2 (1%)

0
3 (1%)

0

0
0

0

0
3 (1%)

1 (,1%)
1 (,1%)

Wd ADRs
Serious ADRs
Serious ADRs

1 (1%)
3 (3%)

Serious ADRs
Serious ADRs
Serious ADRs
Serious infections
Serious infections

3 (3%)

Serious infections
Cancers

0

Deaths
Deaths

0

Deaths
Deaths

1 (2%)

Tofacitinib combination DMARD studies
Wd ADRs
2 (4%)
4 (14%)
Wd ADRs
3 (4%)
5 (4%)
Wd ADRs
15 (8%)
Wd ADRs
14 (7%)

4 (14%)
1 (1%)
15 (8%)
10 (5%)

Wd ADRs
Wd ADRs
Serious ADRs
Serious ADRs
Serious ADRs

36 (11%)
14 (4%)
1 (4%)
10 (5%)
12 (6%)

26 (8%)
20 (6%)
2 (8%)
10 (5%)
10 (5%)

1 (1%)
3 (2%)
3 (1%)

2 (3%)
2 (1%)
4 (2%)

0
0
0
1 (,1%)

0
0
1 (1%)
0

2 (4%)

Serious infections
Serious infections
Serious infections

1 (1%)

Deaths
Deaths
Deaths
Deaths

0
1 (1%)

Deaths
Deaths

1 (,1%)
4 (1%)

1 (,1%)
1 (,1%)
Tofacitinib monotherapy and combination DMARD study
Wd ADRs
437 (11%)
Serious ADRs
630 (15%)
Serious infections
184 (4%)
Cancers
107 (2%)
Cancers
60 (1%)
Deaths
31 (1%)

9 (7%)
2 (4%)

1 (2%)
0

Comparator
DMARD

Adalimumab
3 (6%)

5 (4%)
Methotrexate
25 (13%)
0
2 (1%)
4 (7%)

2 (4%)
1 (2%)
2 (3%)

Adalimumab
1 (2%)

0
Methotrexate
22 (12%)
0
2 (1%)
Methotrexate
5 (3%)
0
Methotrexate
1 (1%)
0
1 (2%)

0
0

Adalimumab
0

0
Methotrexate
0

11 (7%)

2 (7%)
7 (9%)
2 (2%)
3 (3%)

Adalimumab
19 (5%)

0
6 (5%)
2 (2%)
1 (1%)

0

Adalimumab
2 (3%)

0
0
1 (1%)

Adalimumab
0

0
0
0
0

Adalimumab
1 (,1%)

0
1 (1%)

Duration and
reference

6 weeks25
24 weeks28
6 months30
24 months35
12 weeks38
6 weeks25
24 weeks28
6 months30
24 months35
12 weeks38
6 months30
24 months35
12 weeks38
24 months35
6 weeks25
24 weeks28
6 months30
24 months35

12 weeks27
24 weeks29
6 months33
12 months31
12 months32
12 months34
12 weeks27
6 months33
12 months31
24 weeks29
6 months33
12 months31
12 weeks27
24 weeks27
6 months33
12 months31
12 months32
12 months34
60 months36
60 months36
60 months36
.42 months40
60 months36
60 months36

Abbreviations: ADRs, adverse drug effects; bid, twice daily; DMARD, disease-modifying antirheumatic drug; Wd, withdrawal.
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(hazard ratio [HR]: 2.17; [95% confidence interval (CI):
1.76–2.88]), diabetes (1.99 [1.39–2.85]), corticosteroid use
of $7.5 mg (1.4 [1.05–1.88]), and tofacitinib 10 mg bid dose
(1.4 [1.13–1.83]).40 In summary, the risk for serious infections
is relatively low, is not associated with length of study or dose,
and is similar to placebo and other comparators.

Cancers
The reported number of cases of cancer appeared to be low
in these studies, ranging from 0% to 2%, and did not appear
to be related to the dose or duration of treatment (Table 5).
A Phase III 24-month study reported six cases of confirmed
cancer, five of which occurred in those on tofacitinib 5 and
10 mg bid therapy, and one in a patient in the methotrexate
group.35 The types of cancer reported included Burkitt’s
B-cell lymphoma, non-Hodgkin’s lymphoma, colon cancer,
chronic lymphocytic leukemia, prostate cancer, and gastric
cancer. These cases represented 1% of participants from each
group, which is comparable to the 1% of total participants
with malignancies with an incidence rate of 1.0 events per
100 patient-years reported in the long-term extension studies.36 The number of cancers reported was small, so it is difficult to make conclusions other than to report the occurrence.
A recent report that pooled data from prior studies, revealed
107 cancers in 5,671 patients (1.9%) (Table 5).41 The development of cancers was similar to the expected rate in patients
with moderate-to-severe rheumatoid arthritis and did not
appear to increase as the duration of therapy increased.41

Deaths
The occurrence of death reported in tofacitinib studies
appeared to be low and did not appear to be related to dose
or study duration. The death rate ranged from 0% to 1%
in monotherapy and combination studies of 6 weeks to
24 months duration (Table 5). A death rate of less than 1%
was reported during the long-term extension studies, with
an incidence rate of 0.5 events per 100 patient-years.36 The
number of deaths reported in these studies was also small,
making it difficult to make conclusions.

Discussion
In addition to clinical and laboratory measures of disease
activity, patient-reported and other patient-specific outcomes
are also essential measures of effectiveness and safety in evaluating therapy in patients with rheumatoid arthritis. Patients’
perception of pain and ability to perform daily activities are
important measures of their satisfaction with the treatment of
their disease, particularly in a chronic inflammatory disease
such as rheumatoid arthritis. Adverse consequences from
Patient Related Outcome Measures 2016:7
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chronic therapies may lead to discontinuation of therapy
or development of additional disease burden or death. This
focused review of the impact of tofacitinib on these patient
outcomes is needed to further understand and determine the
appropriate use of tofacitinib in rheumatoid arthritis. This
review also extends the number of studies covered in prior
reviews and meta-analyses.
The major results of this review are that tofacitinib
5 mg bid (the approved dosage in the USA) and other doses
are associated with clinically and statistically significant
improvements in the HAQ-DI and other patient-reported
composite outcomes measures. These findings are similar
to findings reported in prior meta-analyses, but this review
includes all patient-centered outcomes mentioned in the
studies reviewed and also includes data from more recent
studies.14,16 Measurements of patient’s pain and global
assessment of disease demonstrated that tofacitinib 5 mg
bid was more effective than both placebo and tofacitinib
1–3 mg bid in both monotherapy and combination therapy
studies.
Total withdrawals and withdrawals due to lack of efficacy
appear to be fewer from the tofacitinib groups than those from
placebo and comparator groups. These observations appear
to be consistent with results from a meta-analysis, which
reported that fewer subjects withdrew from the tofacitinib
group than from the placebo group overall and due to lack
of efficacy.17
Withdrawal rates due to adverse effects or lack of efficacy showed no apparent consistent pattern between dosage
ranges, placebo, or comparator drug categories. The only
noticeable trend was an increase in total withdrawal rates
as the length of the study increased. This increase was also
observed in placebo and comparator drug groups, but was not
associated with tofacitinib dosage group. One monotherapy
study reported a higher withdrawal rate due to lack of efficacy
in the tofacitinib 1–3 mg bid group compared with tofacitinib
5 mg bid and higher doses, but combination studies did not
show this effect.
Our review indicates that withdrawals due to adverse
effects are generally comparable across the tofacitinib
dosage groups, placebo, and other comparator DMARD
groups. This was reported in an earlier meta-analysis of
tofacitinib, which found that although the rate of withdrawal
due to adverse effects was higher in the tofacitinib group
than the placebo group, the difference was not statistically significant.17 Therefore, more recent studies have not
altered these overall findings regarding withdrawal due to
adverse effects for tofacitinib, placebo, and comparator
DMARDs.
submit your manuscript | www.dovepress.com
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Incidences of serious adverse reactions were similar
in all dosage groups, placebo, and comparator studies.
Infection was a common adverse event leading to tofacitinib
withdrawal. However, the risk of serious infections seems
to be similar to placebo and other comparators and was not
associated with study duration. Our observation includes
more recent studies but is similar to that of a meta-analysis,
which reported nonstatistical difference in incidences of
infections between tofacitinib and placebo.12,14,16,17 The
long-term extension study reported independent predictors
associated with increased risk of serious infections, which
included age $65 years, presence of diabetes, corticosteroid use of $7.5 mg od of prednisone (or equivalent), and
tofacitinib 10 mg bid.36 These predictors may help clinicians to determine which patients on tofacitinib to closely
monitor for serious infections. Tofacitinib may decrease
the response to some vaccines and therefore clinicians may
consider administering vaccines prior to initiation of therapy
with tofacitinib when possible to prevent the development
of serious infections.42
The occurrence of cancer and death were low in this
review and did not appear to be associated with study duration
or study group (tofacitinib, placebo, or comparator DMARD).
Cardiovascular disease is a major cause of death in patients
with rheumatoid arthritis and that risk may be decreased
or increased with DMARDs.43,44 However, further study is
needed to determine the impact of tofacitinib on overall death
rates and cardiovascular disease-associated deaths.
The limitations of this review are based on two major
factors: the limitations of the duration and data provided in
the available studies and the nature of the review. The data
collected for this review were primarily from controlled
clinical studies of 1 year or less in duration. Those data may
or may not reflect the impact on patient outcomes during
routine, long-term use of tofacitinib in rheumatoid arthritis.
However, this is expected given the relatively short time
since tofacitinib was approved. As more postmarketing
data are collected, pharmacovigilance studies are needed
to monitor the long-term safety and efficacy of this agent.
The number of patient-reported composite measures was
mostly limited to the HAQ-DI. This is a valid, reliable, and
useful measure, but has its limitations in what is measured.
Additional data on the impact of tofacitinib on the ability
of patients to be productive in their personal and work life
would be valuable additions. Many other patient outcome
measures are available for use in future studies.
As noted above, the submissions for approval of
tofacitinib were approved in the USA and numerous other
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countries, but not by the EMA following their initial and
subsequent examinations in 2013.7 Specifically,
The CHMP [Committee for Medicinal Products for Human
Use] had major concerns about the overall safety profile of
Xeljanz. There were significant and unresolved concerns
about the risk and type of serious infections seen with
tofacitinib, which are related to the immunosuppressant
action of the medicine. These safety concerns also included
a risk of other severe side effects including certain cancers,
gastro-intestinal perforations, (holes in the wall of the
gut), liver damage and problems with increased lipid (fat)
levels in the blood. It was not clear that these risks could
be managed successfully in medical practice. … However,
the lack of robust evidence on prevention of structural
damage with Xeljanz in the proposed dose and population
still contributed to the Committee’s view that the benefits
of treatment did not outweigh significant and unresolved
concerns about safety.7

The FDA approved tofacitinib, indicating the following
on efficacy and concerns related to adverse effects:
In all of the trials, patients treated with Xeljanz experienced
improvement in clinical response and physical functioning
compared to patients treated with placebo. The use of Xeljanz
was associated with an increased risk of serious infections,
including opportunistic infections (infections that occur primarily when the immune system is suppressed), tuberculosis,
cancers and lymphoma. Xeljanz carries a Boxed Warning
regarding these safety risks. Xeljanz treatment is also associated with increases in cholesterol and liver enzyme tests and
decreases in blood counts. The FDA approved Xeljanz with
a Risk Evaluation and Mitigation Strategy (REMS), which
consists of a Medication Guide advising patients about important safety information and a communication plan to inform
health care providers about the serious risks associated with
Xeljanz. To study the long-term effects of Xeljanz on heart
disease, cancer, and serious infections, the FDA is requiring
a postmarketing study that will evaluate two doses of Xeljanz
and include a group of patients on another approved treatment
to serve as a comparison.45

The effect of tofacitinib on cardiovascular events is
complex. Cardiovascular events are increased in patients
with rheumatoid arthritis, particularly in those with increased
disease activity. A recent analysis has revealed that tumor
necrosis factor inhibitors and methotrexate are associated
with decreasing that risk.46 Both tofacitinib and tumor necrosis factor inhibitors decrease the inflammation in patients with
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rheumatoid arthritis. However, tofacitinib leads to an increase
in total, low-density lipoprotein, and high-density lipoprotein cholesterol in patients, resulting in potential addition of
lipid-lowering therapies. It is still too early to determine the
effect of tofacitinib on the risk of cardiovascular events in
patients with rheumatoid arthritis.
This review is limited by its nature as a review rather
than being a prospective or retrospective study. It also lacks
the statistical analyses associated with a meta-analysis.
Additionally, this review included only published papers and
may therefore be limited by publication bias of only those
papers that have demonstrated a positive outcome. However,
this review utilized strict criteria for study inclusion and data
selection and provided data from all recent studies meeting
those criteria.

Conclusion
Based on the evidence available and prior reviews and metaanalyses,12–20 tofacitinib 5 mg bid appears to have a favorable
impact on patient outcomes related to efficacy and safety,
particularly when compared with placebo and comparator
DMARDs. Increases in quality of life and functionality are
significant and the overall discontinuation rate due to adverse
effects and lack of efficacy are similar or better in some studies
versus comparator DMARDs and placebo. Currently, tofacitinib appears to have an important role in the treatment of
rheumatoid arthritis through improvement in these patient
outcomes and a safety profile that is similar to comparator
drugs in the studies presented to date. However, the approval
by some countries but not others plus the requirements for
risk evaluation and mitigation strategies and for postmarketing surveillance raise some concerns about the benefit-to-risk
ratio of tofacitinib. Data from future clinical studies and postmarketing surveillance will clarify the benefit-to-risk ratio of
tofacitinib in the treatment of rheumatoid arthritis.
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